drugset
drugset / Trial / NCT05667415

Treatment of Advance Gastric Cancer With Disulfiram

NCT05667415 ↗

Unknown 40 enrolled First People's Hospital of Hangzhou College of Pharmaceutical Sciences at Zhejiang University · collabThe Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main chemotherapy drug. However, there are many adverse reactions, including bone marrow suppression, gastrointestinal reactions, renal toxicity and neurotoxicity. These adverse reactions can affect the comfort and compliance of patients during treatment. At present, it is necessary to reduce adverse reactions of cisplatin and increase the chemotherapy sensitivity of gastric cancer to cisplatin. Recent studies have found that disulfiram has a potential anti-tumor effect. The disulfiram has shown significant in vivo and in vitro anti-tumor activity in preclinical studies, and has become a potential candidate drug for tumor treatment as an adjuvant in various clinical trials. In this clinical study, cisplatin combined with disulfiram is mainly used to treat advanced gastric cancer.

Timeline

Start
2023-06-01
Primary completion
2025-12-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Disulfiram Small molecule 125 mg Oral
Subject Disulfiram Small molecule 400 mg Oral
Comparator Cisplatin Other / unclassified 80 mg/m2 Intravenous

Indications

No indication recorded.